Population-based analysis of sporadic and type 2 neurofibromatosis- associated meningiomas and schwannomas

Neurology

Volumn 54, Issue 1, 2000, Pages 71-76

  Antinheimo, J ^a,c   Sankila, R ^b   Carpen O ^a   Pukkala, E ^b   Sainio, M ^a   Jaaskelainen J ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

^b FINNISH CANCER REGISTRY   (Finland)

^c HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

Epidemiolog y; Incidence; Meningioma; Meningiomatosis; Neurofibromatosis 2; Schwannoma; Schwannomatosis

Indexed keywords

ADULT; AGED; ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; FAMILIAL DISEASE; FEMALE; FINLAND; GENE MUTATION; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MENINGIOMA; NEURILEMOMA; NEUROFIBROMATOSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PEDIGREE ANALYSIS; PRIORITY JOURNAL;

EID: 0033981059     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/wnl.54.1.71     Document Type: Article

References (25)

1. Fearon ER. Human cancer syndromes: clues to the origin and nature of cancer. Science 1997;278:1043-1050.
2. Evans DGR, Huson SM, Donnai D, et al. A clinical study of type 2 neurofibromatosis. Q J Med 1992;84:603-618.
3. Parry DM, Eldridge R, Kaiser-Kupfer MI, Bouzas EA, Pikus A, Patronas N. Neurofibromatosis 2 (NF2): clinical characteristics of 63 affected individuals and clinical evidence for heterogeneity. Am J Med Genet 1994;52:450-461.
4. Mautner VF, Lindenau M, Baser ME, et al. The neuroimaging and clinical spectrum of neurofibromatosis 2. Neurosurgery 1996;38:880-885.
5. Louis DN, Ramesh V, Gusella JF. Neuropathology and molecular genetics of neurofibromatosis 2 and related tumors. Brain Pathol 1995;5:163-172.
6. MacCollin M, Woodfin W, Kronn D, Short MP. Schwannomatosis: a clinical and pathological study. Neurology 1996;46: 1072-1079.
7. Seppälä M, Sainio M, Haltia M, Kinnunen J, Setälä K, Jääskeläinen J. Multiple schwannomas: schwannomatosis or NF2? J Neurosurg 1998;89:36-41.
8. Jacoby LB, Jones D, Davis K, et al. Molecular analysis of the NF2 tumor-suppressor gene in schwannomatosis. Am J Hum Genet 1997;61:1293-1302.
9. Evans DGB, Mason S, Huson SM, Ponder M, Harding AE, Strachan T. Spinal and cutaneous schwannomatosis is a variant form of type 2 neurofibromatosis: a clinical and molecular study. J Neurol Neurosurg Psychiatry 1997;62:361-366.
10. Butti G, Assietti R, Casalone R, Paoletti P. Multiple meningiomas: a clinical, surgical, and cytogenetic analysis. Surg Neurol 1989;31:255-260.
11. Domenicucci M, Santoro A, D'Osvaldo DH, Delfini R, Cantore GP, Guidetti B. Multiple intracranial meningiomas. J Neurosurg 1989;70:41-44.
12. Wood MW, White RJ, Kernohan JW. One hundred intracranial meningiomas found incidentally at necropsy. J Neuropathol Exp Neurol 1957;16:337-340.
13. Rausing A, Ybo W, Stenflo J. Intracranial meningiomas: a population study of ten years. Acta Neurol Scand 1970;46: 102-110.
14. Lusins JO, Nakagawa H. Multiple meningiomas evaluated by computer tomography. Neurosurgery 1981;9:137-144.
15. Maxwell M, Shih S, Galanopoulos T, Hedley-Whyte T, Cosgrove GR. Familial meningioma: analysis of expression of neurofibromatosis 2 protein Merlin. J Neurosurg 1998;88:562-569.
16. Pulst S-M, Rouleau GA, Marineau C, et al. Familial meningioma is not allelic to neurofibromatosis 2. Neurology 1993;43: 2096-2098.
17. Evans DGR, Huson SM, Donnai D, et al. A genetic study of type 2 neurofibromatosis in the United Kingdom. I. Prevalence, mutation rate, fitness, and confirmation of maternal transmission effect on severity. J Med Genet 1992;29:841-846.
18. Zülch KJ. Histological typing of tumors of the central nervous system. International histological classification of tumours. Geneva: World Health Organization, 1979.
19. Kleihues P, Burger PC, Scheithauer BW. Histological typing of the tumours of the central nervous system. Berlin: Springer-Verlag, 1993.
20. Teppo L, Pukkala E, Lehtonen M. Data quality and quality control of a population-based cancer registry. Acta Oncol 1994; 33:365-369.
21. Gutmann DH, Aylsworth A, Garey JC, et al. The diagnostic evaluation and multidisciplinary management of neurofibromatosis 1 and neurofibromatosis 2. JAMA 1997;278:51-57.
22. Rothman KJ. Modern epidemiology. Boston: Little, Brown, 1986.
23. NIH. National Institutes of Health consensus development conference statement on neurofibromatosis. Neurofibromatosis Res Newsl 1987;3:3-6.
24. Wu CL, Thakker N, Neary W, et al. Differential diagnosis of type 2 neurofibromatosis: molecular discrimination of NF2 and sporadic vestibular schwannomas. J Med Genet 1998;35: 973-977.
25. Sainio M, Strachan T, Blomstedt G, et al. Presymptomatic DNA and MRI diagnosis of neurofibromatosis 2 with mild clinical course in an extended pedigree. Neurology 1995;45: 1314-1322.